The author and journal apologise for an error in the above paper, which appeared in volume 1 part 2, pages 95–102. The error relates to some of the values in Table 1. The author's dataset for HbA1c in 2009 were in different units to data from 2002, which made the calculation of mean HbAb1c incorrect. The mean HbA1c (%) in 2009 should read 7.6 (1.5) and the mean HbA1c (mmol/mol) should read 60.
Table 1.
Cardiovascular risk factor and medication profiles of study population at baseline and in 2009. Values expressed as arithmetic mean (s.d.).
| Measurements in 2002 | Measurements in 2009 | |
|---|---|---|
| HbA1c (%) | 8.0 (1.6) | 7.6 (1.5) |
| HbA1c (mmol/mol) | 64 | 60 |
| eGFR (ml/min per 1.73 m2) | 72 (18) | 70 (27) |
| BMI (kg/m2) | 31.8 (7.6) | 31.0 (6.9) |
| BMI >30 kg/m2 (%) | 55 | 49.2 |
| Systolic BP (mmHg) | 138 (18) | 134 (20) |
| Diastolic BP (mmHg) | 75 (11) | 71 (10) |
| Total cholesterol (mmol/l) | 4.6 (0.9) | 3.9 (0.9) |
| HDL cholesterol (mmol/l) | 1.2 (0.3) | 1.3 (0.4) |
| Percentage of subjects on ACE inhibitors or ARBs | 43.5% (in 2002) | 67.8% (2002–2009) |
| Percentage of subjects on anti-hypertensive medication | 54% (in 2002) | 79.6% (2002–2009) |
| Percentage of subjects on metformin | 58.5% (in 2002) | 80.3% (2002–2009) |
| Percentage of subjects on sulphonylureas | 36% (in 2002) | 61% (2002–2009) |
| Percentage of subjects on insulin | 29.5% (in 2002) | 43.3% (2002–2009) |
| Percentage of subjects on statins | 59% (in 2002) | 85.5% (2002–2009) |
eGFR, estimated glomerular filtration rate by the modification of diet in renal disease equation; BMI, body mass index; BP, blood pressure; HDL, high-density lipoprotein; ACE, angiotensin-converting enzyme; ARB, angiotensin-2 receptor blocker.